Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour. This is a Phase I/II clinical tria

Trial Details

NCT ID
NCT07718243
Phase
PHASE1 / PHASE2
Sponsor
Institute of Cancer Research, United Kingdom
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Bexmarilimab 1mg/kg and nivolumab 1mg/kg
  • Bexmarilimab 3mg/kg and nivolumab 1mg/kg
  • Recommended Phase II Dose
Locations (sample)
  • Manchester, United Kingdom|53.48095,-2.23743
  • Sutton, United Kingdom|51.35,-0.2

Key Eligibility Criteria

  • Histologically proven solid tumour, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient
  • Part B1: Histologically proven NSCLC.
  • Patient has received at least one but not more than three lines of systemic anticancer therapy for metastatic disease.
  • Patient has received at least two cycles of immune checkpoint inhibitor and has demonstrated disease progression within 12 weeks of last dose.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →